Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007195 · ClinicalTrials.gov registry record · Early Phase 1
Smart Olfaction App to Reduce Relapse
A Early Phase 1 study, sponsored by University of Houston.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 132
- Enrollment target
NCT07007195: Recruiting Early Phase 1 study, sponsored by University of Houston.
NCT07007195 is a Early Phase 1 study that is actively recruiting participants, run by University of Houston. The registered enrollment target is 132 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (149% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07007195, a Early Phase 1 study, is actively recruiting participants, sponsored by University of Houston.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
The proposed project aims to refine and test a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation to reduce cigarette craving with an established smartphone-based smoking cessation application. The specific aims of this study are: (1) refine the design and methodology of our olfactory stimulation delivery system (OSDS) and (2) compare, in a pilot randomized controlled trial (RCT), the effects of a smartphone based app for smoking cessation (Smart-T) with and without the OSDS on smoking cessation outcomes.
Primary Outcome
Descriptive data regarding use times and frequency will be assessed.
Interventions
- DEVICE Ad Libitum Use followed by Instructed Use of the Inspire Device
- DEVICE Instructed Use followed by Ad Libitum Use of the Inspire Device
- DEVICE Smart-T Smoking Cessation App with the Inspire Device Condition
- DEVICE Smart-T Smoking Cessation App Without the Inspire Device Condition
- DRUG Nicotine replacement therapy (NRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2026-04-22 |
| Est. Completion | 2027-08-31 |
| Phase | Early Phase 1 |
What NCT07007195 shows while recruiting
NCT07007195 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (149% higher).
The record links to 0 conditions, and to 5 interventions - of which Ad Libitum Use followed by Instructed Use of the Inspire Device is the first listed.
NCT07007195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07007195 about?
NCT07007195 is a clinical study titled "Smart Olfaction App to Reduce Relapse". The proposed project aims to refine and test a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation to reduce cigarette craving with an established smartphone-based smoking cessation application. The specific aims of this study are: (1...
What is the current status of trial NCT07007195?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 132 participants. The study started on 2026-04-22. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT07007195?
The interventions under investigation include: Ad Libitum Use followed by Instructed Use of the Inspire Device (DEVICE), Instructed Use followed by Ad Libitum Use of the Inspire Device (DEVICE), Smart-T Smoking Cessation App with the Inspire Device Condition (DEVICE), Smart-T Smoking Cessation App Without the Inspire Device Condition (DEVICE), Nicotine replacement therapy (NRT) (DRUG).
Who is sponsoring clinical trial NCT07007195?
This trial is sponsored by University of Houston, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07007195's enrollment target sits among peer trials
132 131st of 2000 higher than 1,869 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI